N30 Pharmaceuticals Garners $20,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c911e35a-2f4d-4f78-94f0-67dd8906d885 - Date
11/20/2014 - Company Name
N30 Pharmaceuticals - Mailing Address
3122 Sterling Circle Boulder, CO 80301 USA - Company Description
N30 Pharmaceuticals, LLC is developing s-nitrosothiol therapies for important unmet needs in respiratory diseases. N30’s strategy focuses on administration of GSNO to the human airway, and development of small molecule inhibitors of GSNO reductase. - Website
http://www.n30pharma.com - Transaction Type
Venture Equity - Transaction Amount
$20,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds from the financing will primarily be used to advance the Company’s clinical trial program for N91115, a novel inhibitor S-nitrosoglutathione reluctase (GSNOR). - M&A Terms
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
- Venture Investor
